Leukemia

Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.

The Food and Drug Administration (FDA) approved Xospata (gilteritinib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation that is detected by an FDA-approved test, according to the agency.

The Food and Drug Administration (FDA) approved Daurismo (glasdegib) plus low-dose cytarabine (LDAC) chemotherapy to treat older, newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for chemotherapy.

A Venclexta combination was granted an accelerated approval to treat older patients with acute myeloid leukemia who are ineligible for chemotherapy.

The Food and Drug Administration (FDA) granted a priority review to quizartinib for the treatment of patients with relapsed or refractory FLT3-ITD acute myeloid leukemia (AML).

CLL is the most common type of leukemia in adults across the United State. Here's what you need to know about the disease.

Chronic lymphocytic leukemia can now be managed as a long-term condition, and there are new ways loved ones can help.

The FDA has granted a priority designation to a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) for use in combination with Gazyva (obinutuzumab) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

I shared some advice with another soon-to-be caregiver.

Associating luck with any disease is unfair.

The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma.

While a pediatric cancer diagnosis can obviously impact the child experiencing the disease, psychosocial effects can differentiate how each parent is affected, too.

Techniques open a field of opportunity for stem cell transplant recipients.

The Food and Drug Administration (FDA) approved the use of Lumoxiti (moxetumomab pasudotox-tdfk) for patients with relapsed or refractory hairy cell leukemia (HCL) who previously had at least two prior systemic therapies, including treatment with a purine nucleoside analog.

Equipping with knowledge to improve patient-physician communication and understanding the disease.

An expert provides tips for maximizing time with your oncologist and adhering to oral medication.

An article Honoring the Hero for Colorado's Light the Night Walk.

CAR-T cell therapy has been showing promising in treating children with acute lymphoblastic leukemia, but it can come with significant toxicities.

Recent research showed first-degree relatives of patients with certain types of blood cancers may be at an increased risk for such disease, highlighting the importance of counseling, gene testing and surveillance.

Better treatment options have put chronic lymphocytic leukemia in the spotlight in recent years. But just what is CLL?

An Idaho teenager a boost from one of her idols — former Vice President Joe Biden — during her treatment for acute myeloid leukemia.

The Food and Drug Administration approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for five eligible indications.

Today's approval of Tibsovo, along with the diagnostic tool to determine who should get it, brings a new type of treatment for patients with acute myeloid leukemia.

While there are known risk factors of developing acute myeloid leukemia (AML) – such as a myelodysplastic syndrome diagnosis and receiving chemotherapy and radiotherapy – a diagnosis can still stun and individual. But researchers at Weill Cornell Medicine and New York-Presbyterian recently discovered a genomic pre-malignant biomarker of the disease that can identify people who are at a greater risk for AML.

A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.

An Extraordinary Healer essay honoring KAITLYN WHITEWATER, B.S.N., RN [SAINT FRANCIS HOSPITAL, 7 WEST ONCOLOGY/BONE MARROW TRANSPLANT UNIT, TULSA, OKLAHOMA]

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for glasdegib to treat patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy, according to Pfizer, the manufacturer of the drug.

Nearly 20 percent of hematopoietic stem cell transplant (HSCT) survivors reported using cannabis, not just to ease physical and emotional side effects, but in the hopes that it would help treat their cancer, according to patient survey results presented at the 2018 of American Society of Clinical Oncology (ASCO) Annual Meeting.

The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.